• Company Overview
  • Directors
  • Advisory Board
  • Regulatory & IP
  • Vacancies

About Synapse

Synapse Electroceutical is a leading UK medical technology company with over 15 years experience of developing and producing medical devices grounded in Synapse's unique, clinically proven and patented electroceutical technology.

Incorporated in January 2003, our early work focused on product development, defining intellectual property rights, and refining and securing patents. Sustained growth followed; we now have a strong and committed workforce, our products are recognised for their clinical excellence and value for money across the medical and sport sectors in the UK and worldwide.

Our key product is Accel-Heal, an externally applied electroceutical (EAE) for the treatment of complex wounds. It is a 12 day treatment course consisting of six, battery powered, 48 hour single use units, applied consecutively. Accel-Heal is the only EAE proven to expedite effective healing by changing physiological processes implicated in wound complexity; it targets a key underlying cause of why wounds do not heal and become complex. Accel-Heal EAE is listed within the Drug Tariff, and available for clinical prescribing in England, Wales, Scotland and Northern Ireland. Visit the Accel-Heal product website at www.accelheal.com to find out more.

Developed to provide ease and simplicity of clinical application, based on Synapse's unique electroceutical technology, Accel-Heal EAE improves treatment outcomes, increases healing rates and significantly contributes to treatment cost savings.

Contact us here if you would like to find out more about Synapse, Accel-Heal EAE, our unique electroceutical technology or products in development.

Executive Directors

Andy Boyes
Chief Executive Officer

Andy has enjoyed a successful 32 year career at Smith & Nephew, the FTSE 100 medical technology business engaged in developing, manufacturing, marketing and selling medical devices in the Advanced Wound Management and Advanced Surgical Devices sectors, with sales in excess of £4 billion. Andy is passionate about the wound care sector and helping improve the lives of patients suffering with debilitating complex wounds and since leaving Smith & Nephew has focused on providing Board level support and strategic direction in the sector. Email Andy

Andrew Wildman ACA
Chief Financial Officer

A qualified accountant since 1994, Andrew’s experience includes leading the AIM IPO teams at Deloitte and Ernst & Young where Andrew worked with numerous entrepreneurial businesses, including pharma and biotech companies, on successful IPOs. Email Andrew

John Gildersleeve
Business Development Director

John has over 18 years experience founding disruptive technology start ups. John has achieved both trade sales and public flotations across sectors including e-commerce, entertainment and digital communications. Co-founding Synapse Electroceutical in 2003, John has led the evolution from broad based ‘electrical stimulation' into the focused innovative, approved advanced woundcare product, Accel-Heal. Email John

Non Executive Directors

Reid Thurlow
Non Executive Chairman

Reid, a New Zealand national, has over 25 years experience in the Trust & Financial Services industry and works with HNWI clients on all facets of their wealth and estate planning requirements. Reid sits on the Board of various companies with diversified investments and holdings and is himself an investor in private equity opportunities.

Christa Echtle
Non Executive Director

Christa has over 30 years experience in healthcare. Until 2003, Christa was CEO of a LSE listed company. Since then, Christa has worked as Chair for a number of healthcare investment companies for a variety of Private Equity houses. Christa has also acted as NED on the Board of a LSE listed company. Her particular experience encompass specialist healthcare recruitment, childcare and education services, healthcare IT solutions, healthcare products and services and healthcare innovations.

Clinical & Scientific Advisory Board members:

Dr Robin Martin PhD
Chair

Dr Martin gained his B.Sc. in Biology from the University of Southampton and received his PhD in Genetics from the National Institute of Medical Research, Mill Hill, London in 1983. Following post-doctoral positions at University of Washington, Seattle, the University of Sussex and the University of Sheffield, in 1994 Robin moved to lead a combined team of scientists and surgeons at the Blond McIndoe Research centre (sadly now closed) at the Queen Victoria Hospital in East Grinstead. In 2002, Dr Martin joined Smith & Nephew Advanced Wound Management and held a variety of global Clinical & Scientific Affairs roles over 15 years working on the development and clinical evidence for medical devices such as VERSAJET™, BIOBRANE™, RENASYS™ and PICO™. In 2018 Dr Martin established himself as an independent freelance Scientific Consultant working with clients across a wide range of Wound healing and Reconstructive Surgery topics. Dr Martin is the author/co-author of 63 papers, articles, books and patents.

Dr Ardeshir Bayat BSc (Hons) MB BS PhD

A clinician scientist (reader) based on a tenured contract at the University of Manchester, UK and an honorary professor in the department of dermatology at the University of Cape Town in South Africa. Primary research focus is on wound healing and tissue repair. Using cutting edge experimental tools to gain a deeper insight into the molecular basis of healing, Dr Bayat's laboratory has elucidated mechanisms underlying delayed or excessive responses to tissue repair and applied this knowledge to develop new diagnostic, prognostic and predictive biomarkers as well as targeted therapies.

Dr John Posnett BA, DPhil, Independent Health Economics Consultant

Graduated from the University of York with a BA (first class honours, 1973) and DPhil (1981) in Economics. University of York 1973-2000: Lecturer in economics and later Director of the MSc programme in Health Economics and Professor of Applied Health Economics. Visiting lecturer and researcher at the Universities of Wyoming, Wisconsin, Lehigh and Sydney. 2000-2010: Joined Smith & Nephew as global head of health economics and later Vice President. 2010-present: Vice President at PAREXEL Access Consulting. PAREXEL is a US multinational clinical research organisation and his role has been to build and lead the health economic modelling unit (HEMU) based in the UK, Sweden and the USA. HEMU is an industry leader, providing consultancy support to global pharmaceutical companies in preparation for reimbursement submissions to HTA agencies such as NICE. Experience of multiple successful submissions to NICE, the Drug Tariff and the NICE Medical Technologies Evaluation Programme (MTEP). Published widely in the areas of economics and health economics.

Dr Leanne Atkin PhD, MHSc, RGN

Dr Leanne Atkin is a Lecturer Practitioner at University of Huddersfield additionally being Vascular Nurse Consultant at Mid Yorks NHS Trust. Dr Atkin completed her Masters degree in Advanced Nursing Practice 2010 and her PhD in 2017, her research focus was the treatment and management of peripheral arterial disease. Her passions include leg ulcer management, quality agenda, peripheral arterial disease and advanced wound management. Dr Atkin has published over 50 articles related to vascular diseases, wound assessment, product selection, quality of life and management of leg ulceration.

Dr Amelia Swift RGN MSc PhD PGCE(HE)

Dr Swift is an experienced Senior Lecturer in Nursing with a long held interest in pain management. Dr Swift completed her PhD in 2012 exploring cerebrospinal fluid amino acid and cytokine profiles of patients undergoing hip or knee arthroplasty for osteoarthritis. During this time Dr Swift worked as a nurse researcher attached to a chronic pain team and explored the pain of epidermolysis bullosa, hypothesising that there was a neuropathic component. Over the past four years Amelia has split her time between education and research. In respect of the latter Dr Swift has supported health care professionals to develop clinical academic careers including supporting project development and funding applications. Amelia is passionate about pain education, research and evidence based practice and is the Chair of the British Pain Society Pain Education Special Interest Group and an Associate Editor of Evidence Based Practice.

Synapse quality and excellence

All Synapse electroceutical products are designed and manufactured to conform with the highest standards of quality and safety.

All our products adhere to the quality standards dictated by the International Organisation for Standardization (ISO), Medical Device Directive (MDD), Medical Device Classification and carry the Conformité Européenne (CE) marking. In 2007 Synapse Micro-Current Ltd achieved ISO 9001 Quality Management Systems and ISO 13485 accreditation for the design and manufacture of medical devices for sport and medical applications.  In addition, Synapse has over 50 patents already granted and several pending in key territories of the world as well as a number of registered trademarks.

Synapse Electroceutical medical products are officially certified as Class IIA devices under the medical device directive 93/42/EEC.

Accel-Heal® carries the CE mark having been tested and approved by Notified Body 0120 Accel-Heal® is manufactured to ISO 13485:2016 for the design and manufacture of medical devices.
Click here to download a (pdf) copy of the ISO 13485 certification
Click here to download a (pdf) copy of the ISO 93/42 EEC certification
Click to download a (pdf) copy of the declaration of conformity
All Synapse Electroceutical products carry the CE marking.
For a comprehensive document covering hazards, contra-indications and warranty please visit this link

The Synapse Electroceutical Accel-heal® unit is classified as Class IIA medical devices, having been tested and approved by Notified Body 0120 at meeting the standards of the Medical Devices Directive and the ISO 13485 management system.
iso




Therapeutic Goods Administration (TGA) Approval for Accel-Heal in Australia.

It's great working with us

We love working here and know that you would too. Our teams are knowledgable, enthusiastic and committed. 

Current Vacancies

There are currently no vacancies at Synapse.